Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284354> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4379284354 endingPage "TPS629" @default.
- W4379284354 startingPage "TPS629" @default.
- W4379284354 abstract "TPS629 Background: Patients with breast cancers (BCs) harboring low expression of hormone receptors (HRs) and human epidermal growth factor receptor-2 (HER2) have poor outcomes. Results from the KEYNOTE-522 trial showed that activation of the immune system using a PD1/PD-L1-targeted approach improves outcomes of patients with these high-risk tumors. Antigen-presenting cells (eg, dendritic cells [DCs]) are pivotal for robust cytotoxic responses due to broader activation of the adaptive immune system (ie, CD4 + and CD8 + Th1) against tumor-associated antigens (ie, HER2 or HER3) expressed by high-risk BCs. Methods: DecipHER is a dose-escalation, dose-expansion phase 1 trial designed to assess the safety and the preliminary efficacy of autologous, HER2- and HER3-primed DCs in combination with KEYNOTE 522 regimen in 30 patients. Patients with clinical stage cT1cN1/2 or cT2-4cN0-2, HR 20, HER2-negative BCs are eligible. Patients with inflammatory BC cancer and uncontrolled immune mediated diseases are excluded. After collection through aphaeresis, autologous DCs will be primed ex vivo against 6 HER2 and 8 HER3 immunogenic peptides. Participants will receive alternating ultrasound-guided intratumoral HER2 and HER3 DC injections administered twice a week for 8 doses in total starting 2 weeks prior to neoadjuvant therapy with KEYNOTE 522 regimen. The dose-escalation phase of the study has 3 planned cohorts (10-20, 30-50, 80-100 million DCs) and follows a 3+3 design (maximum n=18). The 12 additional patients enrolled will be treated at the maximum tolerated dose (MTD) in the dose-expansion cohort. The MTD will be defined as the highest dose level at which < 2 of 6 patients experience dose-limiting toxicities (grade ≥ 3 non-hematologic, ; grade ≥ 3 hematologic toxicity thought be at least possibly related to DCs ; any grade 4 nausea, vomiting, or diarrhea [or grade 3 if duration > 3 days]) during the 5 weeks following treatment initiation with DCs. Secondary endpoints include the absolute risk of adverse events, clinical and pathological responses, and recurrence free survival. Tumor tissue, blood and stool samples will be collected for correlative analyses. The study is open at H. Lee Moffitt Cancer Center. Clinical trial information: NCT05504707 ." @default.
- W4379284354 created "2023-06-05" @default.
- W4379284354 creator A5001646635 @default.
- W4379284354 creator A5006005284 @default.
- W4379284354 creator A5011430743 @default.
- W4379284354 creator A5014744153 @default.
- W4379284354 creator A5015112855 @default.
- W4379284354 creator A5016883669 @default.
- W4379284354 creator A5021935697 @default.
- W4379284354 creator A5023384641 @default.
- W4379284354 creator A5036240983 @default.
- W4379284354 creator A5039643514 @default.
- W4379284354 creator A5051916408 @default.
- W4379284354 creator A5059240684 @default.
- W4379284354 creator A5060576547 @default.
- W4379284354 creator A5065440692 @default.
- W4379284354 creator A5067249314 @default.
- W4379284354 creator A5075333609 @default.
- W4379284354 creator A5085929131 @default.
- W4379284354 creator A5090789911 @default.
- W4379284354 date "2023-06-01" @default.
- W4379284354 modified "2023-09-26" @default.
- W4379284354 title "Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial." @default.
- W4379284354 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps629" @default.
- W4379284354 hasPublicationYear "2023" @default.
- W4379284354 type Work @default.
- W4379284354 citedByCount "0" @default.
- W4379284354 crossrefType "journal-article" @default.
- W4379284354 hasAuthorship W4379284354A5001646635 @default.
- W4379284354 hasAuthorship W4379284354A5006005284 @default.
- W4379284354 hasAuthorship W4379284354A5011430743 @default.
- W4379284354 hasAuthorship W4379284354A5014744153 @default.
- W4379284354 hasAuthorship W4379284354A5015112855 @default.
- W4379284354 hasAuthorship W4379284354A5016883669 @default.
- W4379284354 hasAuthorship W4379284354A5021935697 @default.
- W4379284354 hasAuthorship W4379284354A5023384641 @default.
- W4379284354 hasAuthorship W4379284354A5036240983 @default.
- W4379284354 hasAuthorship W4379284354A5039643514 @default.
- W4379284354 hasAuthorship W4379284354A5051916408 @default.
- W4379284354 hasAuthorship W4379284354A5059240684 @default.
- W4379284354 hasAuthorship W4379284354A5060576547 @default.
- W4379284354 hasAuthorship W4379284354A5065440692 @default.
- W4379284354 hasAuthorship W4379284354A5067249314 @default.
- W4379284354 hasAuthorship W4379284354A5075333609 @default.
- W4379284354 hasAuthorship W4379284354A5085929131 @default.
- W4379284354 hasAuthorship W4379284354A5090789911 @default.
- W4379284354 hasConcept C121608353 @default.
- W4379284354 hasConcept C126322002 @default.
- W4379284354 hasConcept C143998085 @default.
- W4379284354 hasConcept C147483822 @default.
- W4379284354 hasConcept C167672396 @default.
- W4379284354 hasConcept C203014093 @default.
- W4379284354 hasConcept C2776872082 @default.
- W4379284354 hasConcept C2779786085 @default.
- W4379284354 hasConcept C2781413609 @default.
- W4379284354 hasConcept C530470458 @default.
- W4379284354 hasConcept C71924100 @default.
- W4379284354 hasConcept C8891405 @default.
- W4379284354 hasConceptScore W4379284354C121608353 @default.
- W4379284354 hasConceptScore W4379284354C126322002 @default.
- W4379284354 hasConceptScore W4379284354C143998085 @default.
- W4379284354 hasConceptScore W4379284354C147483822 @default.
- W4379284354 hasConceptScore W4379284354C167672396 @default.
- W4379284354 hasConceptScore W4379284354C203014093 @default.
- W4379284354 hasConceptScore W4379284354C2776872082 @default.
- W4379284354 hasConceptScore W4379284354C2779786085 @default.
- W4379284354 hasConceptScore W4379284354C2781413609 @default.
- W4379284354 hasConceptScore W4379284354C530470458 @default.
- W4379284354 hasConceptScore W4379284354C71924100 @default.
- W4379284354 hasConceptScore W4379284354C8891405 @default.
- W4379284354 hasIssue "16_suppl" @default.
- W4379284354 hasLocation W43792843541 @default.
- W4379284354 hasOpenAccess W4379284354 @default.
- W4379284354 hasPrimaryLocation W43792843541 @default.
- W4379284354 hasRelatedWork W1722328147 @default.
- W4379284354 hasRelatedWork W2066747782 @default.
- W4379284354 hasRelatedWork W2220102944 @default.
- W4379284354 hasRelatedWork W2560406314 @default.
- W4379284354 hasRelatedWork W2627001382 @default.
- W4379284354 hasRelatedWork W2896532861 @default.
- W4379284354 hasRelatedWork W2902823965 @default.
- W4379284354 hasRelatedWork W2934076975 @default.
- W4379284354 hasRelatedWork W2980453143 @default.
- W4379284354 hasRelatedWork W2342209702 @default.
- W4379284354 hasVolume "41" @default.
- W4379284354 isParatext "false" @default.
- W4379284354 isRetracted "false" @default.
- W4379284354 workType "article" @default.